Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 592-598

  Wan, Min ^a   Hua, Xiang ^a,b   Su, Jun ^b   Thiagarajan, Divya ^b   Frostegård, Anna G ^b   Haeggström, Jesper Z ^a   Frostegård, Johan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Cardiolipin; Inflammation; Leukotrienes; Oxidation

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CALCIUM; CARDIOLIPIN; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; FURA 2; GLYCEROPHOSPHOLIPID; INTERCELLULAR ADHESION MOLECULE 1; LEUKOTRIENE B4; LIPOCORTIN 5; MESSENGER RNA; OXIDIZED CARDIOLIPIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SPECTROPHOTOMETRY; BIOSYNTHESIS; CHEMICALLY INDUCED; METABOLISM; OXIDATION REDUCTION REACTION;

ANNEXIN A5; ARACHIDONATE 5-LIPOXYGENASE; CALCIUM; CARDIOLIPINS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; LEUKOTRIENE B4; MACROPHAGES; NEUTROPHILS; OXIDATION-REDUCTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84909579208     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.913     Document Type: Article

References (46)

1. Schlame M. Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. JLipid Res 2008, 49:1607-1620.
2. Martin W., Hoffmeister M., Rotte C., Henze K. An overview of endosymbiotic models for the origins of eukaryotes, their ATP-producing organelles (mitochondria and hydrogenosomes), and their heterotrophic lifestyle. Biol Chem 2001, 382:1521-1539.
3. Schlame M., Rua D., Greenberg M.L. The biosynthesis and functional role of cardiolipin. Prog Lipid Res 2000, 39:257-288.
4. Chicco A.J., Sparagna G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007, 292:C33-C44.
5. Belikova N.A., Jiang J., Tyurina Y.Y., Zhao Q., Epperly M.W., Greenberger J., et al. Cardiolipin-specific peroxidase reactions of cytochrome C in mitochondria during irradiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2007, 69:176-186.
6. Basova L.V., Kurnikov I.V., Wang L., Ritov V.B., Belikova N.A., Vlasova, et al. Cardiolipin switch in mitochondria: shutting off the reduction of cytochrome c and turning on the peroxidase activity. Biochemistry 2007, 46:3423-3434.
7. Gonzalvez F., Gottlieb E. Cardiolipin: setting the beat of apoptosis. Apoptosis 2007, 12:877-885.
8. Nakagawa Y. Initiation of apoptotic signal by the peroxidation of cardiolipin of mitochondria. Ann N Y Acad Sci 2004, 1011:177-184.
9. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005, 25:1776-1785.
10. Frostegard J. Immunity, atherosclerosis and cardiovascular disease. BMC Med 2013, 11:117.
11. Haeggstrom J.Z., Funk C.D. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011, 111:5866-5898.
12. Cederholm A., Svenungsson E., Jensen-Urstad K., Trollmo C., Ulfgren A.K., Swedenborg J., et al. Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 2005, 25:198-203.
13. Ewing M.M., de Vries M.R., Nordzell M., Pettersson K., de Boer H.C., van Zonneveld A.J., et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol 2011, 31:95-101.
14. Domeij H., Hua X., Su J., Backlund A., Yan Z., Frostegard A.G., et al. Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. Prostaglandins Other Lipid Mediat 2013.
15. Su J., Hua X., Vikstrom M., Leander K., Gigante B., Hellenius M.L., et al. Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study. BMC Cardiovasc Disord 2013, 13:1.
16. Frostegard A.G., Hua X., Su J., Carrero J.J., Heimburger O., Barany P., et al. IgM antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in hemodialysis patients, negatively associated with mortality. Clin Exp Immunol 2013, 441-448.
17. Su J., Frostegard A.G., Hua X., Gustafsson T., Jogestrand T., Hafstrom I., et al. Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus. JRheumatol 2013.
18. Tuominen A., Miller Y.I., Hansen L.F., Kesaniemi Y.A., Witztum J.L., Horkko S. Anatural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2006, 26:2096-2102.
19. Funk C.D. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 2005, 4:664-672.
20. Serezani C.H., Aronoff D.M., Jancar S., Mancuso P., Peters-Golden M. Leukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidase. Blood 2005, 106:1067-1075.
21. Wan M., Sabirsh A., Wetterholm A., Agerberth B., Haeggstrom J.Z. Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. Faseb J 2007, 21:2897-2905.
22. Goodarzi K., Goodarzi M., Tager A.M., Luster A.D., von Andrian U.H. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003, 4:965-973.
23. Yokomizo T., Izumi T., Chang K., Takuwa Y., Shimizu T. AG-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
24. Yokomizo T., Kato K., Terawaki K., Izumi T., Shimizu T. Asecond leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. JExp Med 2000, 192:421-432.
25. Helgadottir A., Manolescu A., Helgason A., Thorleifsson G., Thorsteinsdottir U., Gudbjartsson D.F., et al. Avariant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006, 38:68-74.
26. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004, 36:233-239.
27. Dwyer J.H., Allayee H., Dwyer K.M., Fan J., Wu H., Mar R., et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. NEngl J Med 2004, 350:29-37.
28. Spanbroek R., Grabner R., Lotzer K., Hildner M., Urbach A., Ruhling K., et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A 2003, 100:1238-1243.
29. Qiu H., Gabrielsen A., Agardh H.E., Wan M., Wetterholm A., Wong C.H., et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 2006, 103:8161-8166.
30. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res 2012, 110:875-888.
31. Ionita M.G., van den Borne P., Catanzariti L.M., Moll F.L., de Vries J.P., Pasterkamp G., et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2010, 30:1842-1848.
32. Smith W.L., Urade Y., Jakobsson P.J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 2011, 111:5821-5865.
33. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. JLipid Res 2009, (50 Suppl.):S423-S428.
34. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011, 31:986-1000.
35. Frostegard J., Ulfgren A.K., Nyberg P., Hedin U., Swedenborg J., Andersson U., et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145:33-43.
36. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. JClin Invest 2000, 105:1049-1056.
37. Iyer S.S., Pulskens W.P., Sadler J.J., Butter L.M., Teske G.J., Ulland T.K., et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:20388-20393.
38. Zheng Y., Gardner S.E., Clarke M.C. Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease. Arterioscler Thromb Vasc Biol 2011, 31:2781-2786.
39. Deguchi H., Fernandez J.A., Hackeng T.M., Banka C.L., Griffin J.H. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci U S A 2000, 97:1743-1748.
40. Dashti M., Kulik W., Hoek F., Veerman E.C., Peppelenbosch M.P., Rezaee F. Aphospholipidomic analysis of all defined human plasma lipoproteins. Sci Rep 2012, 1:139.
41. Greig F.H., Kennedy S., Spickett C.M. Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation. Free Radic Biol Med 2012, 52:266-280.
42. Rand J.H., Wu X.X. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999, 82:649-655.
43. Thiagarajan P., Benedict C.R. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. Circulation 1997, 96:2339-2347.
44. Cederholm A., Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 2005, 210:761-768.
45. Ishii H., Hiraoka M., Tanaka A., Shimokado K., Yoshida M. Recombinant Annexin-2 inhibits the progress of diabetic nephropathy in a diabetic mouse model via recovery of hypercoagulability. Thromb Haemost 2007, 97:124-128.
46. Ewing M.M., Karper J.C., Sampietro M.L., de Vries M.R., Pettersson K., Jukema J.W., et al. Annexin A5 prevents post-interventional accelerated atherosclerosis development in a dose-dependent fashion in mice. Atherosclerosis 2012, 221:333-340.